Peripheral neuropathy in colorectal cancer survivors: The influence of oxaliplatin administration. Results from the population-based PROFILES registry

Antoinetta J. M. Beijers; Floortje Mols; Vivianne C. G. Tjan-Heijnen; Catharina G. Faber; Lonneke V. van de Poll-Franse; Gerard Vreugdenhil

doi:10.3109/0284186X.2014.980912

Peripheral neuropathy in colorectal cancer survivors: The influence of oxaliplatin administration. Results from the population-based PROFILES registry

Antoinetta J. M. Beijers^*, Floortje Mols, Vivianne C. G. Tjan-Heijnen, Catharina G. Faber, Lonneke V. van de Poll-Franse, Gerard Vreugdenhil

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Background. Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting side effect of oxaliplatin which can negatively influence quality of life. We aimed to study the influence of cumulative dose, dose schedule and dose reductions of adjuvant oxaliplatin on long-term severity and prevalence of CIPN among colorectal cancer (CRC) survivors. Material and methods. In total 207 patients, diagnosed with CRC between 2000 and 2009 who underwent adjuvant treatment with oxaliplatin, were included. They completed the EORTC QLQ-CIPN20 2-11 years after diagnosis. Data on oxaliplatin administration and acute neuropathy during treatment were extracted from the medical files. Subscales were analyzed with analysis of covariance and neuropathy symptoms with logistic regression analysis. Results. Patients who received cumulative oxaliplatin dose of >= 842 mg/m(2) had a significantly worse EORTC QLQ-CIPN20 sensory score compared to those who received a low cumulative dose of

Original language	English
Pages (from-to)	463-469
Journal	Acta Oncologica
Volume	54
Issue number	4
DOIs	https://doi.org/10.3109/0284186X.2014.980912
Publication status	Published - Apr 2015

Access to Document

10.3109/0284186X.2014.980912Licence: Unspecified

Cite this

@article{13a4bc76597e4a62aa87009ac1bb9f62,

title = "Peripheral neuropathy in colorectal cancer survivors: The influence of oxaliplatin administration. Results from the population-based PROFILES registry",

abstract = "Background. Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting side effect of oxaliplatin which can negatively influence quality of life. We aimed to study the influence of cumulative dose, dose schedule and dose reductions of adjuvant oxaliplatin on long-term severity and prevalence of CIPN among colorectal cancer (CRC) survivors. Material and methods. In total 207 patients, diagnosed with CRC between 2000 and 2009 who underwent adjuvant treatment with oxaliplatin, were included. They completed the EORTC QLQ-CIPN20 2-11 years after diagnosis. Data on oxaliplatin administration and acute neuropathy during treatment were extracted from the medical files. Subscales were analyzed with analysis of covariance and neuropathy symptoms with logistic regression analysis. Results. Patients who received cumulative oxaliplatin dose of >= 842 mg/m(2) had a significantly worse EORTC QLQ-CIPN20 sensory score compared to those who received a low cumulative dose of ",

author = "Beijers, {Antoinetta J. M.} and Floortje Mols and Tjan-Heijnen, {Vivianne C. G.} and Faber, {Catharina G.} and {van de Poll-Franse}, {Lonneke V.} and Gerard Vreugdenhil",

year = "2015",

month = apr,

doi = "10.3109/0284186X.2014.980912",

language = "English",

volume = "54",

pages = "463--469",

journal = "Acta Oncologica",

issn = "0284-186X",

publisher = "Routledge/Taylor & Francis Group",

number = "4",

}

Peripheral neuropathy in colorectal cancer survivors: The influence of oxaliplatin administration. Results from the population-based PROFILES registry. / Beijers, Antoinetta J. M.; Mols, Floortje; Tjan-Heijnen, Vivianne C. G. et al.
In: Acta Oncologica, Vol. 54, No. 4, 04.2015, p. 463-469.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Peripheral neuropathy in colorectal cancer survivors: The influence of oxaliplatin administration. Results from the population-based PROFILES registry

AU - Beijers, Antoinetta J. M.

AU - Mols, Floortje

AU - Tjan-Heijnen, Vivianne C. G.

AU - Faber, Catharina G.

AU - van de Poll-Franse, Lonneke V.

AU - Vreugdenhil, Gerard

PY - 2015/4

Y1 - 2015/4

N2 - Background. Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting side effect of oxaliplatin which can negatively influence quality of life. We aimed to study the influence of cumulative dose, dose schedule and dose reductions of adjuvant oxaliplatin on long-term severity and prevalence of CIPN among colorectal cancer (CRC) survivors. Material and methods. In total 207 patients, diagnosed with CRC between 2000 and 2009 who underwent adjuvant treatment with oxaliplatin, were included. They completed the EORTC QLQ-CIPN20 2-11 years after diagnosis. Data on oxaliplatin administration and acute neuropathy during treatment were extracted from the medical files. Subscales were analyzed with analysis of covariance and neuropathy symptoms with logistic regression analysis. Results. Patients who received cumulative oxaliplatin dose of >= 842 mg/m(2) had a significantly worse EORTC QLQ-CIPN20 sensory score compared to those who received a low cumulative dose of

AB - Background. Chemotherapy-induced peripheral neuropathy (CIPN) is a dose-limiting side effect of oxaliplatin which can negatively influence quality of life. We aimed to study the influence of cumulative dose, dose schedule and dose reductions of adjuvant oxaliplatin on long-term severity and prevalence of CIPN among colorectal cancer (CRC) survivors. Material and methods. In total 207 patients, diagnosed with CRC between 2000 and 2009 who underwent adjuvant treatment with oxaliplatin, were included. They completed the EORTC QLQ-CIPN20 2-11 years after diagnosis. Data on oxaliplatin administration and acute neuropathy during treatment were extracted from the medical files. Subscales were analyzed with analysis of covariance and neuropathy symptoms with logistic regression analysis. Results. Patients who received cumulative oxaliplatin dose of >= 842 mg/m(2) had a significantly worse EORTC QLQ-CIPN20 sensory score compared to those who received a low cumulative dose of

U2 - 10.3109/0284186X.2014.980912

DO - 10.3109/0284186X.2014.980912

M3 - Article

C2 - 25417732

SN - 0284-186X

VL - 54

SP - 463

EP - 469

JO - Acta Oncologica

JF - Acta Oncologica

IS - 4

ER -